PH27351A - Cytotoxic drug conjugates - Google Patents

Cytotoxic drug conjugates

Info

Publication number
PH27351A
PH27351A PH39050A PH39050A PH27351A PH 27351 A PH27351 A PH 27351A PH 39050 A PH39050 A PH 39050A PH 39050 A PH39050 A PH 39050A PH 27351 A PH27351 A PH 27351A
Authority
PH
Philippines
Prior art keywords
drug conjugates
cytotoxic drug
cytotoxic
conjugates
drug
Prior art date
Application number
PH39050A
Other languages
English (en)
Inventor
George Joseph Cullinan
Bennett Coleman Laguzza
William Leonard Scott
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PH27351A publication Critical patent/PH27351A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PH39050A 1988-08-08 1989-08-04 Cytotoxic drug conjugates PH27351A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/230,084 US5006652A (en) 1988-08-08 1988-08-08 Intermediates for antibody-vinca drug conjugates

Publications (1)

Publication Number Publication Date
PH27351A true PH27351A (en) 1993-06-21

Family

ID=22863896

Family Applications (1)

Application Number Title Priority Date Filing Date
PH39050A PH27351A (en) 1988-08-08 1989-08-04 Cytotoxic drug conjugates

Country Status (15)

Country Link
US (1) US5006652A (fr)
EP (1) EP0354728A3 (fr)
JP (1) JPH02131499A (fr)
KR (1) KR900002804A (fr)
CN (1) CN1040205A (fr)
AR (1) AR245368A1 (fr)
AU (1) AU619329B2 (fr)
DK (1) DK382989A (fr)
HU (1) HU206377B (fr)
IL (1) IL91182A0 (fr)
MX (1) MX164971B (fr)
NZ (1) NZ230200A (fr)
PH (1) PH27351A (fr)
PT (1) PT91372A (fr)
ZA (1) ZA895908B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
AU633867B2 (en) * 1989-02-02 1993-02-11 Eli Lilly And Company Delivery of cytotoxic agents
US5272253A (en) * 1991-07-01 1993-12-21 Eli Lilly And Company Cluster conjugates of drugs with antibodies
ES2049656B1 (es) * 1992-10-08 1994-11-16 Lilly Co Eli Grupos de conjugados de farmacos con anticuerpos.
GR1001459B (el) * 1992-10-08 1993-12-30 Lilly Co Eli Σύμπλεγμα συζυγών φαρμάκων με αντισώματα.
US5773001A (en) * 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US20030119724A1 (en) * 1995-11-22 2003-06-26 Ts`O Paul O.P. Ligands to enhance cellular uptake of biomolecules
CN100406065C (zh) 2000-12-01 2008-07-30 细胞工厂治疗公司 糖基化/半乳糖基化肽、双官能接头和核苷酸单体/多聚体的缀合物以及相关的组合物和使用方法
EP1389209B1 (fr) * 2001-04-24 2009-04-08 Purdue Research Foundation Mimetiques de folate et ses conjugues se liant au recepteur de folate
KR20040106547A (ko) * 2002-05-15 2004-12-17 엔도사이트, 인코포레이티드 비타민-마이토마이신 공액체
US7601332B2 (en) 2003-01-27 2009-10-13 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
CN101098854B (zh) 2004-07-23 2012-12-05 恩多塞特公司 二价连接体及其轭合物
CN101175757B (zh) * 2005-03-16 2012-11-14 恩多塞特公司 蝶酸及其缀合物的合成和纯化
JP2009504783A (ja) * 2005-08-19 2009-02-05 エンドサイト，インコーポレイテッド ビンカアルカロイド、類似体および誘導体のリガンド結合体
RU2470668C2 (ru) * 2005-08-19 2012-12-27 Эндосайт, Инк. Конъюгаты лиганда с несколькими лекарственными средствами
US20100104626A1 (en) * 2007-02-16 2010-04-29 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
CN104127878A (zh) * 2007-03-14 2014-11-05 恩多塞特公司 结合配体连接的微管溶素递药缀合物
BRPI0812970A2 (pt) * 2007-06-25 2019-09-24 Endocyte Inc conjugados contendo espaçadores hidrofílicos
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
EP2209374B1 (fr) 2007-10-25 2014-12-03 Endocyte, Inc. Tubulysines et leurs procédés de préparation
WO2013126797A1 (fr) 2012-02-24 2013-08-29 Purdue Research Foundation Ciblage du récepteur de la cholécystokinine de type b pour imagerie et thérapie
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
EA201590622A1 (ru) 2012-10-16 2015-10-30 Эндосайт, Инк. Конъюгаты для доставки лекарственного средства, содержащие не встречающиеся в природе аминокислоты, и способы применения
HK1220626A1 (zh) 2013-03-15 2017-05-12 The Centre For Drug Research And Development 具细胞毒性和抗有丝分裂的化合物以及其使用方法
KR102384740B1 (ko) 2013-12-27 2022-04-07 자임워크스 인코포레이티드 약물 접합체를 위한 설폰아마이드-함유 연결 시스템
ES2905569T3 (es) 2014-09-17 2022-04-11 Zymeworks Inc Compuestos citotóxicos y antimitóticos y métodos para utilizarlos

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203898A (en) * 1977-08-29 1980-05-20 Eli Lilly And Company Amide derivatives of VLB, leurosidine, leurocristine and related dimeric alkaloids
FI820020A7 (fi) * 1981-01-12 1982-07-13 Lilly Industries Ltd Immunoglobuliinikonjugaatteja.
US4631190A (en) * 1981-06-26 1986-12-23 Shen Wei C Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
CA1203164A (fr) * 1982-03-09 1986-04-15 Thomas J. Mckearn Conjugats d'anticorps
GR79899B (fr) * 1983-03-30 1984-10-31 Lilly Industries Ltd
GR81790B (fr) * 1983-04-29 1984-12-12 Omnichem Sa
LU86157A1 (fr) * 1985-11-12 1987-06-26 Omnichem Sa Nouveau procede de fabrication de conjugues de la vinblastine et de ses derives
US4675400A (en) * 1985-06-17 1987-06-23 Eli Lilly And Company Bifunctional derivatives of 4-desacetyl indole-dihydroindole alkaloids
EP0232693A3 (fr) * 1985-12-16 1988-04-06 La Region Wallonne Conjugués de la vinblastine et de ses dérivés, procédé pour leur préparation et compositions pharmaceutiques les contenant
GB8610551D0 (en) * 1986-04-30 1986-06-04 Hoffmann La Roche Polypeptide & protein derivatives
IL82579A0 (en) * 1986-05-27 1987-11-30 Lilly Co Eli Immunoglobulin conjugates
US4997913A (en) * 1986-06-30 1991-03-05 Oncogen pH-sensitive immunoconjugates and methods for their use in tumor therapy
FR2610198B1 (fr) * 1987-02-03 1990-06-15 Ire Celltarg Sa Conjugues d'hydrazide d'alcaloide de vinca lie a une immunoglobuline, procede de preparation et compositions pharmaceutiques en comprenant
IL89043A0 (en) * 1988-01-27 1989-08-15 Lilly Co Eli Antibody conjugates

Also Published As

Publication number Publication date
PT91372A (pt) 1990-03-08
MX164971B (es) 1992-10-09
KR900002804A (ko) 1990-03-23
EP0354728A3 (fr) 1991-04-10
DK382989D0 (da) 1989-08-04
AU619329B2 (en) 1992-01-23
HUT50488A (en) 1990-02-28
JPH02131499A (ja) 1990-05-21
IL91182A0 (en) 1990-03-19
AU3933989A (en) 1990-02-08
DK382989A (da) 1990-02-09
ZA895908B (en) 1991-04-24
HU206377B (en) 1992-10-28
AR245368A1 (es) 1994-01-31
US5006652A (en) 1991-04-09
CN1040205A (zh) 1990-03-07
NZ230200A (en) 1991-11-26
EP0354728A2 (fr) 1990-02-14

Similar Documents

Publication Publication Date Title
AU619328B2 (en) Cytotoxic drug conjugates
AU619329B2 (en) Cytotoxic drug conjugates
GB8822857D0 (en) Pharmaceutical formulations
EP0335545A3 (en) Pharmaceutical formulations for parenteral use
GB9200417D0 (en) Cytotoxic drug therapy
ZA892315B (en) Pharmaceutical formulations for parenteral use
HUT53126A (en) Antibody medicament conjugates
GB2228922B (en) Packaging drugs
EP0443027A4 (en) Drug composition
ZA899948B (en) Pharmaceutical preparation
IE892533L (en) Cytotoxic drug conjugates
IE892534L (en) Cytotoxic drug conjugates
GB8807505D0 (en) Pharmaceutical combinations
ZA893463B (en) Drug adsorbates
GB8901158D0 (en) Administering drugs
IE883489L (en) Drug-monoclonalantibody conjugates
IL92583A0 (en) Tolerogenic immunoglobulin-protein conjugates
GB8820175D0 (en) Pharmaceutical formulations
GB8820271D0 (en) Pharmaceutical formulations
GB8820272D0 (en) Pharmaceutical formulations
GB8825297D0 (en) Pharmaceutical formulations
GB8820343D0 (en) Pharmaceutical formulations
GB8813402D0 (en) Pharmaceutical formulations
GB8816609D0 (en) Pharmaceutical formulations
GB8804790D0 (en) Pharmaceutical formulations